全文获取类型
收费全文 | 2596篇 |
免费 | 149篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 41篇 |
妇产科学 | 61篇 |
基础医学 | 364篇 |
口腔科学 | 36篇 |
临床医学 | 248篇 |
内科学 | 531篇 |
皮肤病学 | 55篇 |
神经病学 | 300篇 |
特种医学 | 143篇 |
外科学 | 297篇 |
综合类 | 14篇 |
预防医学 | 136篇 |
眼科学 | 20篇 |
药学 | 237篇 |
中国医学 | 6篇 |
肿瘤学 | 266篇 |
出版年
2023年 | 19篇 |
2022年 | 56篇 |
2021年 | 68篇 |
2020年 | 31篇 |
2019年 | 54篇 |
2018年 | 73篇 |
2017年 | 61篇 |
2016年 | 70篇 |
2015年 | 80篇 |
2014年 | 81篇 |
2013年 | 111篇 |
2012年 | 205篇 |
2011年 | 193篇 |
2010年 | 101篇 |
2009年 | 92篇 |
2008年 | 177篇 |
2007年 | 164篇 |
2006年 | 158篇 |
2005年 | 169篇 |
2004年 | 149篇 |
2003年 | 134篇 |
2002年 | 109篇 |
2001年 | 34篇 |
2000年 | 40篇 |
1999年 | 30篇 |
1998年 | 24篇 |
1997年 | 16篇 |
1996年 | 17篇 |
1995年 | 21篇 |
1994年 | 12篇 |
1993年 | 7篇 |
1992年 | 12篇 |
1991年 | 18篇 |
1990年 | 11篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 6篇 |
1986年 | 15篇 |
1985年 | 8篇 |
1984年 | 10篇 |
1983年 | 12篇 |
1981年 | 6篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1974年 | 7篇 |
1972年 | 9篇 |
1971年 | 7篇 |
1967年 | 8篇 |
1945年 | 9篇 |
排序方式: 共有2767条查询结果,搜索用时 0 毫秒
31.
Martinelli P Maruotti GM Oppedisano R Agangi A Mazzarelli LL Votino C Quarantelli M Iaccarino V 《Journal of minimally invasive gynecology》2007,14(6):758-763
The study objective was to assess the feasibility and the efficacy of bilateral uterine artery embolization (BUAE) for the treatment of cervical pregnancy. The design was a series of 3 cases of viable cervical pregnancy diagnosed by transvaginal ultrasonography and treated by means of BUAE and subsequent uterine curettage. Three women with viable cervical pregnancy underwent BUAE and subsequent uterine curettage in the department of obstetrics and gynecology, High Risk Pregnancy Center, University "Federico II" of Naples. Measurements included surgical outcomes and preservation of fertility. The treatment was effective in all cases. Two patients resumed normal menstruation about 1 month after the procedure, whereas 1 patient underwent a hysterectomy 2 weeks after embolization because of acute ischemic degeneration of a concomitant myoma. The conservative management of cervical pregnancy with angiographic BUAE is a feasible and effective option, even if subsequent hysterectomy may be required. Counseling is necessary. 相似文献
32.
Gennaro Daniele Clorinda Schettino Laura Arenare Domenico Bilancia Fabio Farinati Piera Federico Stefano Tamberi Gino Crivellari Sandro Barni Raffaella Tortora Francesco Izzo Antonio Frassoldati Luigi Cavanna Claudia Mucciarini Luigi Bolondi Angelo Dinota Filippo Pelizzaro Maria Carmela Piccirillo Piera Gargiulo Massimo Di Maio Ciro Gallo Francesco Perrone Bruno Daniele 《肝癌研究(英文版)》2021,7(7):52-65
Aim: Only patients with good liver function {[Child-Pugh (CP)] A class} were eligible for trials testing sorafenib as first-line treatment of hepatocellular car... 相似文献
33.
Zorcolo L Rosman AS Restivo A Pisano M Nigri GR Fancellu A Melis M 《Annals of surgical oncology》2012,19(9):2822-2832
Background
Complete pathologic response (CPR) after neoadjuvant chemoradiotherapy (combined modality treatment, CMT) for rectal cancer seems associated with improved survival compared to partial or no response (NPR). However, previous reports have been limited by small sample size and single-institution design.Methods
A systematic literature review was conducted to detect studies comparing long-term results of patients with CPR and NPR after CMT for rectal cancer. Variables were pooled only if evaluated by 3 or more studies. Study end points included rates of CPR, local recurrence (LR), distant recurrence (DR), 5-year overall survival (OS), and disease-free survival (DFS).Results
Twelve studies (1,913 patients) with rectal cancer treated with CMT were included. CPR was observed in 300 patients (15.6%). CPR and NPR patient groups were similar with respect to age, sex, tumor size, distance of tumor from the anus, and stage of disease before treatment. Median follow-up ranged from 23 to 46?months. CPR patients had lower rates of LR [0.7% vs. 2.6%; odds ratio (OR) 0.45, 95% confidence interval (CI) 0.22?C0.90, P?=?0.03], DR (5.3% vs. 24.1%; OR 0.15, 95% CI 0.07?C0.31, P?=?0.0001), and simultaneous LR?+?DR (0.7% vs. 4.8%; OR 0.32, 95% CI 0.13?C0.79, P?=?0.01). OS was 92.9% for CPR versus 73.4% for NPR (OR 3.6, 95% CI 1.84?C7.22, P?=?0.002), and DFS was 86.9% versus 63.9% (OR 3.53, 95% CI 1.62?C7.72, P?=?0.002).Conclusions
CPR after CMT for rectal cancer is associated with improved local and distal control as well as better OS and DFS. 相似文献34.
Erika J. Wolf Ci-Di Chen Xiang Zhao Zhenwei Zhou Filomene G. Morrison Nikolaos P. Daskalakis Annjanette Stone Steven Schichman Jaclyn Garza Grenier Dana Fein-Schaffer Bertrand R. Huber Traumatic Stress Brain Research Group Carmela R. Abraham Mark W. Miller Mark W. Logue 《Neuropsychopharmacology》2021,46(4):721
35.
Angelone T Quintieri AM Brar BK Limchaiyawat PT Tota B Mahata SK Cerra MC 《Endocrinology》2008,149(10):4780-4793
Circulating levels of catestatin (Cts; human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga-null mice with Cts prevents blood pressure elevation, indicating a direct role of Cts in preventing hypertension. This notable vasoreactivity prompted us to test the direct cardiovascular effects and mechanisms of action of wild-type (WT) Cts and naturally occurring human variants (G364S-Cts and P370L-Cts) on myocardial and coronary functions. The direct cardiovascular actions of WT-Cts and human variants were determined using the Langendorff-perfused rat heart. WT-Cts dose-dependently increased heart rate and coronary pressure and decreased left ventricular pressure, rate pressure product and both positive and negative LVdP/dt. WT-Cts not only inhibited phospholamban phosphorylation, but also the inotropic and lusitropic effects of WT-Cts were abolished by chemical inhibition of beta2-adrenergic receptors, Gi/o protein, nitric oxide or cGMP, indicating involvement of beta2-adrenergic receptors-Gi/o protein-nitric oxide-cGMP signaling mechanisms. In contrast, G364S-Cts did not affect basal cardiac performance but abolished isoproterenol-induced positive inotropism and lusitropism. P370L-Cts decreased rate pressure product and inhibited only isoproterenol-induced positive inotropism and lusitropism by 70%. Cts also inhibited endothelin-1-induced positive inotropism and coronary constriction. Taken together, the cardioinhibitory influence exerted on basal mechanical performance and the counterregulatory action against beta-adrenergic and endothelin-1 stimulations point to Cts as a novel cardiac modulator, able to protect the heart against excessive sympathochromaffin overactivation, e.g. hypertensive cardiomyopathy. 相似文献
36.
BACKGROUND/AIMS: Small interfering RNAs (siRNAs) are an efficient tool to specifically inhibit gene expression by RNA interference. Since hepatitis C virus (HCV) replicates in the cytoplasm of liver cells without integration into the host genome, RNA-directed antiviral strategies are likely to successfully block the HCV replication cycle. Additional benefit might arise from inhibition of cellular cofactors of HCV replication, such as proteasome alpha-subunit 7 (PSMA7) or Hu antigen R (HuR). METHODS: In this study, we investigated direct and cofactor-mediated inhibition of HCV by a panel of DNA-based retroviral vectors expressing siRNAs against highly conserved HCV sequences or the putative HCV cofactors PSMA7 and HuR. Effects were determined in HCV IRES-mediated translation assays and subgenomic HCV replicon cells. RESULTS: PSMA7- and HuR-directed siRNAs successfully inhibited expression of the endogenous genes, and PSMA7 and HuR silencing significantly diminished HCV replicon RNA and NS5B protein levels. HCV-directed siRNAs substantially inhibited HCV IRES-mediated translation and subgenomic HCV replication. Combinations of PSMA7- and HuR-directed siRNAs with HCV-directed siRNAs revealed additive HCV RNA inhibitory effects in monocistronic replicon cells. CONCLUSIONS: A dual approach of direct- and cofactor-mediated inhibition of HCV replication might avoid selection of mutants and thereby become a powerful strategy against HCV. 相似文献
37.
Nuzzo F Morabito A De Maio E Di Rella F Gravina A Labonia V Landi G Pacilio C Piccirillo MC Rossi E D'Aiuto G Thomas R Gori S Colozza M De Placido S Lauria R Signoriello G Gallo C Perrone F de Matteis A 《Critical reviews in oncology/hematology》2008,66(2):171-180
Within an ongoing multicentre phase 3 randomised trial (ELDA, cancertrials.gov ID: NCT00331097), early breast cancer patients, 65-79 years old, with average to high risk of recurrence, are randomly assigned to receive CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1-8) or docetaxel (35 mg/m2 days 1-8-15), every 4 weeks. Here we report an unplanned safety analysis prompted by an amendment introducing creatinine clearance as a tool to adjust methotrexate dose. Before such change, 101 patients with a median age of 70 were randomly assigned CMF (53 patients) or docetaxel (48 patients). At least one grades 3-4 toxic event of any type was reported in 40 (75.5%) and 19 (39.6%) patients with CMF and docetaxel, respectively (p=0.0002). Grades 3-4 hematological events were observed in 37 (69.8%) vs. 4 (8.3%) cases (p<0.0001) and grades 3-4 non-hematological toxicity in 12 (22.6%) vs. 15 (31.2%) patients (p=0.11), with CMF and docetaxel, respectively. A higher incidence of anemia, neutropenia, thrombocytopenia and febrile neutropenia was reported with CMF. Constipation, mucositis, nausea and vomiting were more common with CMF; diarrhoea, abdominal pain, dysgeusia, neuropathy and liver toxicity were more frequent with docetaxel. No significant interaction was found between the occurrence of severe toxicity and baseline variables, including creatinine clearance and geriatric activity scales. In conclusion, weekly docetaxel appears to be less toxic than CMF in terms of hematological toxicity. 相似文献
38.
39.
Purpose
Morphine ARER is a novel oral, abuse-deterrent, extended-release (ER) formulation of morphine sulfate with physical and chemical properties that deter misuse and abuse by nonoral routes of administration. Here we evaluate the relative bioavailability of morphine ARER and extended-release morphine.Methods
This single-dose, 2-treatment, 2-period, 2-sequence, randomized crossover study in healthy adult subjects compared the relative bioavailability of morphine ARER 100 mg to that of ER morphine 100 mg in the fasted condition. At 12 and 1.5 hours before dosing and 12 hours after dosing, all subjects received a 50-mg oral naltrexone tablet to minimize opioid-related side effects. Pharmacokinetic parameters including the AUC0–t, AUC0–∞, and Cmax of morphine and its metabolite morphine-6-glucuronide (M6G) were determined at various times up to 48 hours postdose. The bioequivalence of morphine ARER and ER morphine was determined using an ANOVA of the least-squares mean values of morphine and M6G bioavailability.Findings
Forty-nine subjects completed the study. Both morphine ARER and ER morphine exhibited peak plasma morphine and M6G concentrations of ~30 ng/mL and ~200 ng/mL, respectively, at 3 hours postdose. The 90% CIs of the ln-transformed values of morphine AUC0–t, AUC0–∞, and Cmax were within the 80% to 125% range for bioequivalence. M6G values also indicated bioequivalence of morphine ARER and ER morphine. The most common adverse events were nausea and somnolence.Implications
These data show that, in these subjects, morphine ARER was bioequivalent to ER morphine, a treatment for pain with well-established efficacy and safety profiles. 相似文献40.